Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627517 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
A NA study of Type 1 Diabetes Mellitus and Sleep Quality, sponsored by Luna Diabetes.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06627517: Active NA study of Type 1 Diabetes Mellitus and Sleep Quality, sponsored by Luna Diabetes.
NCT06627517 is a NA study of Type 1 Diabetes Mellitus and Sleep Quality that is active but no longer recruiting, run by Luna Diabetes. The registered enrollment target is 120 participants, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06627517, a NA study of Type 1 Diabetes Mellitus and Sleep Quality, is active but no longer recruiting, sponsored by Luna Diabetes.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. The study device does not replace long-acting, correction, or mealtime insulin. The study will involve applying the study device before bed for a period of 13 weeks. The overall study length is approximately 17 weeks. The study aims to evaluate whether the study device is safe and if it lowers blood sugar levels in people who have consistently high blood sugar during sleep and at wake.
Conditions Studied
Interventions
- DEVICE Episodic overnight patch pump
Study Locations (3)
California
- Diablo Clinical Research - Walnut Creek
Colorado
- Barbara Davis Center for Diabetes - Aurora
Minnesota
- International Diabetes Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT06627517 still lists
NCT06627517 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (30% lower).
The record links to 2 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Episodic overnight patch pump is the first listed.
NCT06627517 reports a single indexed study location in California, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06627517 about?
NCT06627517 is a clinical study titled "Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus". The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. The study device does not replace long-acting, correct...
What is the current status of trial NCT06627517?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-11-22. Estimated completion is 2025-12.
What conditions does trial NCT06627517 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, Sleep Quality.
What interventions are being tested in trial NCT06627517?
The interventions under investigation include: Episodic overnight patch pump (DEVICE).
Who is sponsoring clinical trial NCT06627517?
This trial is sponsored by Luna Diabetes, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06627517 being conducted?
This trial has 3 study locations across California, Colorado, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06627517's enrollment target sits among peer trials
120 27th of 112 higher than 83 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI